Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

Summary

This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.

Timeline

Start

2011-10

Primary completion

2012-10

Completion

2012-10

Outcome

Met primary endpoint

paper Compared with alternative treatment, low-dose spironolactone was associated with significant decrease in office systolic BP (-33 vs. -14 mmHg; p = 0.024) PMID 27007793 ↗

paper and in diastolic BP (-14 vs. -5 mmHg; p = 0.006). PMID 27007793 ↗

Publications

• Djoumessi RN, Noubiap JJ, Kaze FF, Essouma M, Menanga AP, Kengne AP, Mbanya JC, Sobngwi E. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. BMC Res Notes. 2016 Mar 23;9:187. doi: 10.1186/s13104-016-1987-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Spironolactone	Small molecule	25 mg	—

Indications